Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 206


Copper Transporter ATP7A (Copper-Transporting P-Type ATPase/Menkes ATPase) Limits Vascular Inflammation and Aortic Aneurysm Development: Role of MicroRNA-125b.

Sudhahar V, Das A, Horimatsu T, Ash D, Leanhart S, Antipova O, Vogt S, Singla B, Csanyi G, White J, Kaplan JH, Fulton D, Weintraub NL, Won Kim H, Ushio-Fukai M, Fukai T.

Arterioscler Thromb Vasc Biol. 2019 Sep 26:ATVBAHA119313374. doi: 10.1161/ATVBAHA.119.313374. [Epub ahead of print]


Drug-induced exanthema and resolution in treatment of Bipolar I Disorder with Lamotrigine and Aripiprazole.

Houghton H, Ash D, Elder C, Lauriello J.

Bipolar Disord. 2019 Sep;21(6):568-570. doi: 10.1111/bdi.12820. Epub 2019 Sep 13. No abstract available.


The nature and extent of emotion recognition and empathy impairments in children showing disruptive behaviour referred into a crime prevention programme.

Hunnikin LM, Wells AE, Ash DP, van Goozen SHM.

Eur Child Adolesc Psychiatry. 2019 Jun 1. doi: 10.1007/s00787-019-01358-w. [Epub ahead of print]


Copper transporter ATP7A interacts with IQGAP1, a Rac1 binding scaffolding protein: role in PDGF-induced VSMC migration and vascular remodeling.

Ashino T, Kohno T, Sudhahar V, Ash D, Ushio-Fukai M, Fukai T.

Am J Physiol Cell Physiol. 2018 Dec 1;315(6):C850-C862. doi: 10.1152/ajpcell.00230.2018. Epub 2018 Sep 26.


School Shootings - 'It wouldn't happen here'?

Haeney O, Ash D, Galletly C.

Aust N Z J Psychiatry. 2018 May;52(5):405-407. doi: 10.1177/0004867418771515. No abstract available.


Misleading Guidance From Pharmacogenomic Testing.

Rahman T, Ash DM, Lauriello J, Rawlani R.

Am J Psychiatry. 2017 Oct 1;174(10):922-924. doi: 10.1176/appi.ajp.2017.16121353. No abstract available.


Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase.

Ji Y, Bowersock A, Badour AR, Vij N, Juris SJ, Ash DE, Mohanty DK.

Biochimie. 2017 Feb;133:103-111. doi: 10.1016/j.biochi.2016.12.010. Epub 2016 Dec 26.


Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE; ProtecT Study Group*.

N Engl J Med. 2016 Oct 13;375(15):1425-1437. doi: 10.1056/NEJMoa1606221. Epub 2016 Sep 14.


10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group.

N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.


Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.

Mason MD, Moore R, Jones G, Lewis G, Donovan JL, Neal DE, Hamdy FC, Lane JA, Staffurth JN; ProtecT Study Group.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e92-e100. doi: 10.1016/j.clon.2016.05.011. Epub 2016 Jul 12.


Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group.

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582. Epub 2016 Aug 17.


Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52. Erratum in: Br J Cancer. 2018 Feb 13;:.


Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy.

Engelstad K, Sklerov M, Kriger J, Sanford A, Grier J, Ash D, Egli D, DiMauro S, Thompson JL, Sauer MV, Hirano M.

Hum Reprod. 2016 May;31(5):1058-65. doi: 10.1093/humrep/dew033. Epub 2016 Mar 2.


Recovery-based services in a psychiatric intensive care unit - the consumer perspective.

Ash D, Suetani S, Nair J, Halpin M.

Australas Psychiatry. 2015 Oct;23(5):524-7. doi: 10.1177/1039856215593397. Epub 2015 Jul 6.


Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; Australian Prostate Cancer BioResource; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.


Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells.

Ash D, Subramanian M, Surolia A, Shaha C.

Am J Cancer Res. 2015 Jan 15;5(2):481-97. eCollection 2015.


Five-year review of absconding in three acute psychiatric inpatient wards in Australia.

Gerace A, Oster C, Mosel K, O'Kane D, Ash D, Muir-Cochrane E.

Int J Ment Health Nurs. 2015 Feb;24(1):28-37. doi: 10.1111/inm.12100. Epub 2014 Dec 1.


Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells.

Tripathi R, Ash D, Shaha C.

J Cell Mol Med. 2014 Nov;18(11):2275-86. doi: 10.1111/jcmm.12386. Epub 2014 Sep 11.


Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC; ProtecT study group.

Lancet Oncol. 2014 Sep;15(10):1109-18. doi: 10.1016/S1470-2045(14)70361-4. Epub 2014 Aug 19. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.


Slow and sustained nitric oxide releasing compounds inhibit multipotent vascular stem cell proliferation and differentiation without causing cell death.

Curtis BM, Leix KA, Ji Y, Glaves RS, Ash DE, Mohanty DK.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):208-12. doi: 10.1016/j.bbrc.2014.05.087. Epub 2014 May 27.

Supplemental Content

Loading ...
Support Center